ArticleCatheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions2026
The High-Sensitivity C-Reactive Protein-Albumin-Lymphocyte Index Is a Prognostic Marker for All-Cause and Cardiovascular Mortality in Patients With ST-Elevation Myocardial Infarction.
Article in Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The High-Sensitivity C-Reactive Protein-Albumin-Lymphocyte Index Is a Prognostic Marker for All-Cause and Cardiovascular Mortality in Patients With ST-Elevation Myocardial Infarction.Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundInflammation and immune dysfunction may worsen the prognosis of patients with ST-segment elevation myocardial infarction (STEMI).
aimsThis study aimed to assess whether the high-sensitivity C-reactive protein-albumin-lymphocyte index (hsCALLYI) could be used to predict the prognosis of STEMI patients who received emergency percutaneous coronary intervention (PCI) treatment.
methodsParticipants were categorized into three groups based on hsCALLYI tertiles. To assess the prognostic significance of hsCALLYI in predicting both all-cause and cardiovascular mortality, Kaplan-Meier survival curves were constructed, followed by Cox proportional hazards regression modeling and time-dependent receiver operating characteristic (ROC) curve analysis.
resultsA lower level of hsCALLYI demonstrated a significant correlation with elevated mortality risk from all causes (hazard ratio [HR] = 9.826, 95% CI = 3.091-31.235, p < 0.001) and cardiovascular mortality (HR = 15.035, 95% CI = 3.353-67.408, p < 0.001). The area under the ROC curve of hsCALLYI for all-cause mortality was 0.696 (p < 0.05), and the area under the ROC curve of hsCALLYI for cardiovascular mortality was 0.695 (p < 0.05).
conclusionhsCALLYI emerged as a significant independent prognostic indicator for both all-cause and cardiovascular mortality in STEMI patients undergoing emergency PCI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.